id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0309-0007,FDA,FDA-2014-E-0309,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-02T04:00:00Z,2016,8,2016-08-02T04:00:00Z,,2016-08-03T00:11:09Z,,0,0,090000648214fcde
FDA-2014-E-0309-0006,FDA,FDA-2014-E-0309,"Determination of Regulatory Review Period for Purposes of Patent
Extension; FULYZAQ",Notice,Determinations,2015-12-10T05:00:00Z,2015,12,2015-12-10T05:00:00Z,2016-02-09T04:59:59Z,2015-12-10T17:04:57Z,2015-31097,0,0,0900006481d9aed7
FDA-2014-E-0309-0005,FDA,FDA-2014-E-0309,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-05T05:00:00Z,2015,11,2015-11-05T05:00:00Z,,2015-11-05T21:28:05Z,,0,0,0900006481d17c39
FDA-2014-E-0309-0004,FDA,FDA-2014-E-0309,Letter from the U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-03-25T04:00:00Z,2015,3,2015-03-25T04:00:00Z,,2015-03-25T16:15:17Z,,0,0,0900006481a63c72
FDA-2014-E-0309-0003,FDA,FDA-2014-E-0309,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2014-05-27T04:00:00Z,2014,5,2014-05-27T04:00:00Z,,2014-05-27T15:29:24Z,,0,0,09000064817158a6
FDA-2014-E-0309-0002,FDA,FDA-2014-E-0309,"Patent Extension from Napo Pharmaceuticals, Inc. (on behalf of McCarter & English, LLP)",Other,Application,2014-03-14T04:00:00Z,2014,3,2014-03-14T04:00:00Z,,2014-03-14T14:29:42Z,,0,0,090000648166613d
FDA-2014-E-0309-0001,FDA,FDA-2014-E-0309,U.S. Patent and Trademark Office,Other,Letter(s),2014-03-14T04:00:00Z,2014,3,2014-03-14T04:00:00Z,,2015-01-13T16:42:25Z,,0,0,0900006481666139